Clinical Trials

Inclusion Criteria:

• age 18 years or older
• histologic evidence of non-small cell lung carcinoma
• immediate plans for a clinically directed tumor biopsy to determine EGFR mutation status
• new diagnosis of advanced or metastatic disease or recent progression on systemic therapy for advanced or metastatic disease
• the absence of an active second active malignancy
• an understanding of the protocol and its requirements, risks, and discomforts
• the ability and willingness to sign an informed consent

Exclusion Criteria: 

• pregnancy or lactation (for females). Pregnancy and lactation will affect cfDNA quality relative to the evaluation of tumor specific alterations. 
• "Pregnancy (by self-report of pregnancy status)"
• inability on the part of the patient to understand the informed consent or be compliant with the protocol